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Abstract
The current tests of anxiety in mice and rats used in preclinical research include
the elevated plus-maze (EPM) or zero-maze (EZM), the light/dark box (LDB),
and the open-field (OF). They are currently very popular, and despite their poor
achievements, they continue to exert considerable constraints on the develop-
ment of novel approaches. Hence, a novel anxiety test needs to be compared
with these traditional tests, and assessed against various factors that were identi-
fied as a source of their inconsistent and contradictory results. These constraints
are very costly, and they are in most cases useless as they originate from flawed
methodologies. In the present report, we argue that the EPM or EZM, LDB, and
OF do not provide unequivocal measures of anxiety; that there is no evidence of
motivation conflict involved in these tests. They can be considered at best, tests
of natural preference for unlit and/or enclosed spaces. We also argued that phar-
macological validation of a behavioral test is an inappropriate approach; it stems
from the confusion of animal models of human behavior with animal models of
pathophysiology. A behavioral test is developed to detect not to produce symp-
toms, and a drug is used to validate an identified physiological target. In order
to overcome the major methodological flaws in animal anxiety studies, we pro-
posed an open space anxiety test, a 3D maze, which is described here with high-
lights of its various advantages over to the traditional tests.
Abbreviations
EPM, elevated plus-maze; EZM, elevated zero-maze; LDB, light/dark box; OAAI,
open arms avoidance index; OF, open-field; POAE, percent open arm entries;
POAT, percent open arm time; TUA, tests of unconditioned anxiety.
Introduction
Tests of unconditioned anxiety (TUA) consist mainly of
the elevated plus-maze (EPM) or zero-maze (EZM), the
light–dark box (LDB) and the open-field (OF). These
tests are all intensively used, particularly the EPM, in the
study of the neurobiological basis of anxiety and in
screening for novel targets and anxiolytic compounds.
These TUA have been subjects of numerous reviews,
which highlighted their shortcomings concerning their
sensitivity and some aspects of their validity (Belzung and
Griebel 2001; Belzung 2001; Crabbe et al. 1999; Cryan
and Sweeney 2011; Dawson and Tricklebank 1995; Griebel
and Holmes 2013; Hogg 1996; Milner and Crabbe 2008;
O’Leary et al. 2013; Rodgers 1997; Rodgers and Dalvi
1997; Treit et al. 2010), followed by various recommenda-
tions and protocol improvement proposals (Bailey et al.
2006; Bouwknecht and Paylor 2008; Crawley et al. 1997;
Crawley 1999; Kalueff et al. 2007; Sousa et al. 2006; van
der Staay and Steckler 2001; Wahlsten et al. 2003; Wahl-
sten 2001; W€urbel 2002). Despite their poor achieve-
ments, they remain as popular as ever (Haller and Alicki
2012; Haller et al. 2013; Herzog et al. 2000).
In most reports, there is an implicit assumption that
the construct validity of TUA has been achieved with
their sensitivity to benzodiazepine drugs, although limited
mostly to this class of drugs (Belzung 2001; Griebel and
Holmes 2013; Cryan and Sweeney 2011; Haller and Alicki
2012; Rodgers 1997). Inconsistent and conflicting results
have been accounted for by differences in mice and rats
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innate state or trait anxiety (Andreatini and Bacellar
2000; Avgustinovich et al. 2000; Belzung and Griebel
2001; Bourin et al. 2007; Goes et al. 2009, 2015; Griebel
et al. 1996) and/or by various test environment factors
(Albrechet–Souza et al. 2005; Crabbe et al. 1999; Fonken
et al. 2009; Violle et al. 2009; Garcia et al. 2005; Heredia
et al. 2012; Abramov et al. 2008; Lewejohann et al. 2006;
Chesler et al. 2002; Loss et al. 2015; Ravenelle et al.
2014). However, post hoc research studies appear unable
to support these accounts (Goes et al. 2015; Jones and
King 2001; Arndt et al. 2009; Augustsson et al. 2003;
Becker and Grecksch 1996; Nicholson et al. 2009; Hagen-
buch et al. 2006; Cohen et al. 2001; Lewejohann et al.
2006; Pellow et al. 1985; Wolfer et al. 2004). Inconsistent
and conflicting results continue to occupy central stage in
animal studies of anxiety. Critical analysis remains limited
within the constraints of traditional approaches and
methodologies. Authors of a novel test and/or method-
ological approach are unable to publish or secure funding
support without the test having been compared with the
EPM, and demonstrated positive sensitivity to benzodi-
azepines and 5-HT drugs. Sensitivity to differences
between strains of rats or mice is considered insufficient.
In addition, a novel test needs to be assessed against vari-
ous factors that were identified as a source of inconsisten-
cies and contradictions in the traditional tests. Hence, a
novel test remains viewed as an adaptive strategy, in con-
tinuity with the traditional approaches. With the above
constraints, it is very difficult for a novel behavioral
approach to progress and succeed.
In the present report, we examine some major issues
that have been overlooked, or inadvertently misrepre-
sented in various critical assessments of the methodolo-
gies currently in use in animal studies of anxiety. We also
describe a novel open anxiety test, a 3D maze that we
proposed to overcome the flaws and limitations of the
current tests. We will argue that (1) the assumption of
the presence of a conflict between two opposite motiva-
tional drives in the TUA remains to be verified. While the
avoidance drive is apparent in these tests, the approach
drive has yet to be demonstrated; (2) that a number of
methodological validity concepts are incorrectly attributed
to behavioral tests; this is mainly due to the lack of dis-
tinction between animals models of human behavior and
animal models of human pathology. Pharmacological
validity is the consequence of this poor distinction.
The review starts with a definition of anxiety and some
clarifications regarding the uses and misuses of method-
ological concepts in animal anxiety literature reviews. A
description of the main TUA, including the 3D maze, is
provided. This is followed by a discussion of the differ-
ences between these while highlighting major flaws,
pitfalls, and limitations. Results obtained in the 3D maze
with different strains of mice, and with drugs such as dia-
zepam, fluoxetine, and dizocilpine will be described.
Animal Models and Validity
In a recent review, Ennaceur (2014) described various
methodological flaws that undermine the validity of the
current TUA. He reported that these tests do not provide
unequivocal measures of anxiety as the conflict hypothesis
cannot be verified. He also pointed out that in numerous
critical review analysis, attributes of animal models of
human anxiety disorders are wrongly associated to behav-
ioral tests of anxiety (Belzung and Lemoine 2011; Belzung
and Griebel 2001; Cryan and Holmes 2005; Cryan and
Sweeney 2011; Geyer and Markou 1995; Griebel and
Holmes 2013; Homberg 2013; Hendriksen and Groenink
2015; Nemeroff 2002; Silverman et al. 2010; Willner 1997;
Shekhar et al. 2001). We argue here, that a behavioral test
provides a set of conditions under which a mental state
or condition is assessed. A behavioral test does not pro-
duce a psychiatric or neurological disorder; it does not
produce symptoms as requested by the authors of these
critical reviews. If a behavioral test is sensitive enough, it
should be able to detect symptoms. However, to achieve
this sensitivity with consistency and reliability, a behav-
ioral test needs to demonstrate that it is measuring the
construct that it is meant to measure, and that it not
measuring a different construct which it may be confused
with. It should demonstrate discriminant validity, and
provide unequivocal measures of anxiety.
An animal model of human behavior represents a the-
ory of a cognitive or an emotional process, which is
translated from humans to animals. A behavioral test is
developed primarily and specifically to verify and support
a theory of cognition or emotion; it can also be used to
verify a theory of a psychopathology, but it is not devel-
oped for a particular psychopathology. For instance, a
behavioral test can be developed to assess the effects of
various factors and experimental manipulations on mem-
ory in normal subjects. It can be used to determine the
presence or absence of memory impairment in animal
models of schizophrenia in the same way it is used to
assess memory in animal models of Alzheimer’s disease,
stroke, autism, asthma, or any pathophysiological condi-
tion. The same is true for an anxiety test. There is no
such thing as a behavioral test suitable only for a
particular class of drugs, a particular brain structure or a
pathophysiology.
An animal model of human psychopathology is devel-
oped with the aim that such a model displays symptoms
characteristic of a particular disorder. These can be
achieved with various experimental interventions (drug
administrations, genetic manipulations, lesion applica-
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tions). The induction of these symptoms requires that the
underlying physiological and/or neurochemical basis of
these symptoms have been already determined. Up-to-
date neuroscientists have been relying intensively on
drugs from serendipitous discovery, which appear to alle-
viate symptoms. These drugs have been used to determine
drug targets and neurochemical pathways that account
for the disorders. They provide the basis upon which
most animal models of a psychopathology have been
developed. This pharmacological validation approach rests
on a fragile assumption that a drug has specificity and
efficacy in the treatment of a particular psychopathology.
Pharmacological validity creates a sort of association in
which a drug forms an intrinsic component of the behav-
ioral test. Two serious risks emerge from such an associa-
tion. The first one is that a behavioral test can be viewed
as specific to a particular class of drugs. The second risk
is dogmatization of assumptions. The fundamental basis
upon which anxiolytic properties were attributed to both
benzodiazepines and SSRIs, and the fundamental basis
upon which the EPM, EZM, LDB, and OF are established
as tests of anxiety remain almost untouchable. Hence, we
witnessed over more than 30 years that a lack of consis-
tency and reliability of the current tests of anxiety was
accounted for by almost anything that a scientist can
hypothesis about, except the validity of the construct that
these behavioral tests were set to measure.
An animal model of a neurological or a psychiatric
disorder can be achieved using a behavioral test with vali-
dated measures of the construct it intends to measure,
and the determination of the physiological and/or neuro-
chemical changes that occurred during the exposition to
the test. This traditional method involves normal animals,
and can be based on the use of strains of rats and mice
that express differences in emotionality. The association
of the measured construct to specific physiological and
neurochemical changes will determine drug targets, and
will facilitate the design of the type of pathological model
for further investigation. This strategy provides a strong
rational for the investigation of the neurobiological basis
of anxiety free from the fertile constraints of pharmaco-
logical validity.
Definitions of Fear and Anxiety
Fear is defined as a negative emotional state associated
with the perception of imminent or present threat to
wellbeing or survival. It is a defensive reaction, which
facilitates escape and avoidance of impending identifiable
danger. Anxiety, on the other hand, is defined as a nega-
tive emotional state associated with the perception of
potential or ambiguous threat. Like fear, it is a defensive
reaction, but characterized by a feeling of apprehension,
uncertainty, worry, uneasiness, or tension stemming from
the anticipation of potential threat or negative outcomes.
Hence, in fear conditions, humans and animals face an
unambiguous situation; they can avoid the threatening
stimulus or escape to safety. The aversive stimulus does
not carry an incentive that diminishes or moderates the
need to avoid or escape. However, in anxiety conditions,
humans and animals face an ambiguous situation. They
are unable to avoid/escape or approach the perceived
threat stimulus. They experience a high level of uncer-
tainty and unpredictability as the threat stimulus appears
associated with both positive and negative outcomes.
Therefore, a test of unconditioned anxiety needs to
demonstrate construct validity, which comprises a num-
ber subset of validity items. We are able to cover only the
most important one, in this review. Construct validity
originated for early validation process of psychometric
tests, and therefore a note of caution is necessary when
applying this to animal behavioral tests – some adjust-
ments and adaptations are required.
 Face validity, that is at face value, the test conditions
and the elicited responses should conduct to a general
agreement whether these two appear to involve anxiety.
For instance, agreement on novelty- or unfamiliarity-
induced fear response, agreement on the equivalence
and ambiguity of the whole test situation that evokes
fear-induced avoidance/escape and approach, and
agreement on a particular response or a set of
responses that are selected to measure anxiety.
 Discriminant validity, that is the test evokes and pro-
vides measures of anxiety rather than fear-induced
escape or avoidance response. This should be demon-
strated by comparing the behavior of animals in fear-
induced anxiety setting to animals in fear-induced
avoidance setting using the same test and manipulating
a single element of the test. For instance, removing the
ambiguity of fear-evoking stimuli or the uncertainty of
the response outcome so that animals can escape or
avoid to terminate fear and anxiety. Another element
of discriminant validity concerns the measurement of
the anxiety response. The test should be able to dis-
criminate between confounding factors, in particular
when hyperactivity, impulsivity or impaired cognitive
processes are manifested in the presence of an anxio-
genic stimulus.
 Convergent validity is often conducted to determine
whether the measurements from two or more tests of
the same construct converge to produce comparable,
convergent results. This is only possible if at least one
of these tests has already established construct validity,
which in our view is not the case with the TUA. How-
ever, convergent validity is also concerned with the
ª 2016 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
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extent to which the different measures of the construct
(anxiety) are related to each other. For instance, in the
EPM, discriminant validity is concerned with various
spatiotemporal and ethological parameters that are
thought to measure anxiety such as open arm entries,
open time entries and their respective percent values,
as well as risk assessment behaviors. Unfortunately, the
accumulated evidence demonstrates no convergence
between these measurements (see Tables 1 and 2 on
spatiotemporal parameters, and Ennaceur 2014 on
ethological parameters).
 Predictive validity refers to the ability of a test of anxiety
to predict the performance of the same or comparable
sample population in other provoking anxiety situations.
However, it has been extended to refer also to the ability
of a behavioral test of anxiety to predict the anxiolytic
efficacy of known drugs (i.e., diazepam or fluoxetine).
This assumes that a reference drug has a well-established
specificity, that its primary effect (i.e., anxiolysis) is
clearly distinguishable from and not confounded with its
secondary effects (i.e., sedation, relaxation, psychomotor
stimulation, or impaired perceptual and cognitive pro-
cesses). In some reports, predictive validity is associated
with the ability of an anxiety test to predict novel drugs,
which are believed to have anxiolytic properties. In this
case, there are two unverified assumptions, one concern-
ing the validity of the behavioral test itself and the other
one concerning the anxiolytic properties of the drug.
Failure to detect an effect on anxiety can invalidate nei-
ther the test nor the drug.
The Tests of Unconditioned of
Anxiety
The EPM consists of four arms radiating from a central
platform forming a plus sign shape; it is elevated from the
ground with two opposed walled arms and two opposed
open arms (Fernandes and File 1996; Handley and
Mithani 1984). Another variant of this test is the EZM,
which consists of a circular runway divided in two
enclosed quadrants opposite to two open quadrants
(Shepherd et al. 1994; Weiss et al. 1998). In the EPM, a
mouse or a rat is released in the central area (Griebel et al.
2000; Holmes et al. 2003; Rodgers et al. 2002a,b), whereas
in the EZM a mouse or a rat is released in one of the
enclosed quadrants (Heredia et al. 2013; Holmes et al.
2003). The LDB consists of two chambers one lit and the
other dark connected through a small opening or a tunnel
(Aulich 1976; Crawley and Goodwin 1980; Hasco€et and
Bourin 1998). Animals are placed either in the middle of
the lit chamber (Bourin and Hascoe¨t 2003; Costall et al.
1989; Holmes et al. 2003) or the dark chamber (Heredia
et al. 2014; Mu¨ller et al. 2003; Oitzl et al. 2001). The OF
consists of either a cylindrical, rectangular, or a square
box with open top, and with (van Gaalen and Steckler
2000) or without (Heredia et al. 2014; Lalonde and Stra-
zielle 2008; van Gaalen and Steckler 2000) an object in the
center of the field. In the OF without object, animals are
released from the central arena (Heredia et al. 2014; Hall
et al. 2000; Lalonde and Strazielle 2008) or from one of
the corners (Kelley et al. 2003; Kulesskaya and V~oikar
2014). In the OF with object, animals are released from
one of the corner of the arena (Hall et al. 2000; Kelley
et al. 2003). In all these tests, mice or rats mice are left to
explore the mazes for 5–10 min. In the case of the OF,
animals can be exposed for more than 10 min.
The 3D Maze Open Space Anxiety
Test
The 3D maze is a modified version of the radial arm
maze (Ennaceur et al. 2008). It was originally developed
for assessing spatial navigation from different view per-
spectives (Mostafa et al. 2002). It consists of nine arms.
Each arm is attached to a bridge, which radiates from a
nonagonal shaped central hub. Mice can access an arm
only by crossing a bridge. The bridges can be level with
the arms providing a standard radial maze configuration.
They can also be tilted upward or downward providing a
maze with raised or lowered arm configurations, respec-
tively (Fig. 1). All parts of the maze apparatus are unpro-
tected; hence, mice are exposed to a complete open space.
In our anxiety experiments, we used the raised arms con-
figuration; the bridge to each arm formed a slope, which
was inclined upward by about 40°. A mouse is trans-
ported in a small beaker; this is tilted gently over the cen-
ter platform of the maze for the release of the mouse,
which is then let free to explore for 12 min.
The validity of the open space anxiety tests, which
include the 3D maze and the elevated platform with
attached slopes, and the validity of the TUA were discussed
in a recent review (Ennaceur 2014). The 3D maze offers a
completely open space. It is based on the view that in anxi-
ety conditions, humans and animals face an ambiguous sit-
uation. They are (or feel) unable to avoid/escape or
approach the perceived threat stimulus. Therefore, a test of
anxiety needs to expose animals to conditions which
involve uninformative or ambiguous stimuli, and that the
outcomes from the choice between these stimuli are uncer-
tain. When exposed to an open space, animals try to escape
or explore to find a refuge. This motivation to escape is
exploited in the 3D maze to provide measures of anxiety.
Hence, apparent escape routes are made available, but the
distant segments of these routes are left inaccessible to
2016 | Vol. 4 | Iss. 2 | e00223
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immediate or direct sensory perception. The experience of
fear from the unfamiliar and open space is therefore com-
plicated by the ambiguity of the choices and the uncer-
tainty of the choice outcomes. Entries into the distal
segments of the test environment are used to determine
anxiety in animals. A low level of anxiety or a reduction in
anxiety is reflected by an increase in the number of entries
into the arms of the maze.
Natural Preference Versus Security
and Safety Versus Conflict
motivations
In the TUA, untreated animals have been reported to
show a natural preference for the protected/unlit space
and a natural aversion of the unprotected/lit space. For
most authors, TUA set into play a conflict between these
Table 1. Sample data from various research reports illustrating the consistency between results and concordances between elevated plus-maze
(EPM) test parameters in the study of mouse strain differences
Strains OA EA Total DIFF POAE POAT OAAI References
C57BL/6JOla 12.0 2.8 14.8 9.2 81 61 29 Mathiasen et al. 2008 (T2)
BALB/cByJ 17.0 8.0 25.0 9.0 68 90 21 Trullas and Skolnick 1993
BALBc/J 6.4 1.6 8.0 4.8 80 69 26 Trullas and Skolnick 1993
C57BL/6JOla 10.0 5.3 15.3 4.7 65 46 44 Mathiasen et al. 2008 (T1)
C3H/HeN 10.4 6.6 17.0 3.7 61 52 44 Trullas and Skolnick 1993
CBA/J 9.6 6.4 16.0 3.2 60 58 41 Trullas and Skolnick 1993
C3H/HeJ 8.4 5.6 14.0 2.8 60 69 36 Trullas and Skolnick 1993
NMRI 8.7 6.3 15.0 2.4 58 37 53 Griebel et al. 2000
NMRI 8.3 6.9 15.2 1.4 55 40 53 Mathiasen et al. 2008 (T2)
NMRI 9.2 9.3 18.6 0.1 49 38 56 Mathiasen et al. 2008 (T1)
C3H/HeJ 1.5 2.5 4.0 1.0 37 29 67 Griebel et al. 2000
C3H/HeJ 1.5 3.0 4.5 1.5 33 13 77 Yilmazer–Hanke et al. 2003
SJL/J 8.7 10.3 19.0 1.5 46 23 66 Griebel et al. 2000
C57BL/6J 3.5 5.5 9.0 2.0 39 1 80 Yilmazer–Hanke et al. 2003
CBA/J 2.6 5.4 8.0 2.9 32 28 70 Griebel et al. 2000
BALB/cByJ 3.6 7.4 11.0 3.7 33 15 76 Griebel et al. 2000
DBA/2Ola 7.3 11.6 18.9 4.3 39 43 59 Mathiasen et al. 2008 (T1)
BALB/cJ 6.5 11.0 17.0 4.5 38 21 70 Yilmazer–Hanke et al. 2003
A/J 3.0 8.0 11.0 5.1 27 65 54 O’Leary et al. 2013
DBA 2.4 7.6 10.0 5.2 24 11 83 Griebel et al. 2000
DBA/2Ola 4.9 10.3 15.2 5.4 32 66 51 Mathiasen et al. 2008 (T2)
BALBc/J 7.8 13.2 21.0 5.5 37 21 71 O’Leary et al. 2013
DBA/2J 2.8 8.3 11.0 5.5 25 62 57 Trullas and Skolnick 1993
NMRI 6.0 11.5 17.5 5.5 34 34 66 Yilmazer–Hanke et al. 2003
BALB/cByJ 8.1 13.9 22.0 5.7 37 41 61 O’Leary et al. 2013
C3H/HeJ 8.8 16.3 25.0 7.5 35 42 62 O’Leary et al. 2013
A/J 0.2 7.8 8.0 7.7 2 27 86 Trullas and Skolnick 1993
C57BL/6J 3.5 11.6 15.0 8.1 23 37 70 Griebel et al. 2000
C57BL/6ByJ 2.2 10.8 13.0 8.6 17 34 75 Trullas and Skolnick 1993
DBA/2J 2.5 13.5 16.0 11.0 16 36 74 Yilmazer–Hanke et al. 2003
C57BL/6J 0.8 13.2 14.0 12.3 6 35 80 Trullas and Skolnick 1993
129S1/SvImJ 6.3 18.8 25.0 12.5 25 5 85 O’Leary et al. 2013
C57BL/6J 7.2 22.8 30.0 15.6 24 19 79 O’Leary et al. 2013
SJL/J 11.3 27.7 39.0 16.4 29 35 68 O’Leary et al. 2013
DBA/2J 7.7 24.3 32.0 16.6 24 6 85 O’Leary et al. 2013
AKR 5.8 23.2 29.0 17.4 20 36 72 O’Leary et al. 2013
FVB/NJ 9.8 31.2 41.0 21.3 24 15 81 O’Leary et al. 2013
BTBR 7.4 29.6 37.0 22.2 20 46 67 O’Leary et al. 2013
The above data were mostly estimated from average group values of available test parameters in tables or graphs. They are presented in the order
of the difference (DIFF) between open arm (OA) and enclosed arms (EA) entries. Negative values indicate a preference for open arms. T1 and T2
in Mathiasen et al. 2008 refer to Table 1 and table 2, respectively. The above data sample demonstrates lack of concordance between the EPM
test parameters. It also demonstrates that the same strain of mice can be low anxiety in one study and high anxiety in another one. Note also
that, in most research reports, the POAE and POAT are below 50%.
OA, open arm entries; EA, enclosed arm entries; Total, OA + EA; DIFF, EA-OA; POAE, percent open arm entries; POAT, percent open arm time;
OAAI, open arm avoidance index.
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two natural tendencies. The motivation to stay in a pro-
tected/unlit space, which is naturally associated with
safety and security, opposes the motivation to explore an
unprotected/lit space, which is naturally associated with
possible threat and danger. Diazepam and other benzodi-
azepine drugs appear to moderate and lessen this conflict.
In the EPM, animals are reported to display an aver-
sion of the open arms from the second minute of a test
session and, this aversion is increased further throughout
the test session and, in subsequent sessions (Arabo et al.
2014; Casarrubea et al. 2013; Espejo 1997; Holmes and
Rodgers 1998; Rosa et al. 2000; Treit et al. 1993). In addi-
tion, a single previous experience of the EPM or LDB has
been reported to reduce or abolish the effects of both
anxiolytic and anxiogenic drugs (Dawson et al. 1994;
Escarabajal et al. 2003; Holmes et al. 2001; Holmes and
Rodgers 2003; Rodgers and Shepherd 1993). Furthermore,
this persistent aversion of the open arms and this “one-
trial tolerance” has been reported for various strains of
mice and rats (Cook et al. 2002; Izıdio et al. 2005; Rod-
gers and Cole 1993). Numerous interpretations have been
provided to account for these behaviors, but none has
considered the possibility that the current TUA promotes
a natural preference for a protected and/or an unlit space
over risk taking (see Ennaceur 2014). A number of studies
suggest that, in a natural or experimental open field envi-
ronment, the primary function of the behavior of mice
and rats is to optimize security (Alstott and Timberlake
2009; Whishaw et al. 2006; Yaski and Eilam 2007). Hence,
whether impulsivity, curiosity or attempt to find an
escape route would have led animals initially to make a
few entries into the open and/or lit space, these entries
can only decline within and between sessions. The preva-
lence of security and safety provided by the enclosed
spaces is likely to reduce or eliminate the incentive to
explore other parts of a test apparatus, which are lit
and/or unprotected. Indeed, in our previous studies,
when a refuge was provided during the test, both anxious
(BALB/c) and less anxious (C57/BL6J and CD-1) strains
of mice did not venture into the arms of the 3D maze
(Ennaceur et al. 2008) and into the steep slopes attached
to an elevated platform (Michalikova et al. 2010); they
spent most of the time inside the refuge. These results are
supported by other studies, which suggest that the behav-
ior of rats and mice in a novel environment is directed
toward optimizing safety (Alstott and Timberlake 2009;
Whishaw et al. 2006; Yaski and Eilam 2007). Rats and
mice, like other animals of prey in the wild, are most
likely to experience anxiety when they are in the open
than when they are hiding in a burrow. The interpreta-
tion of the behavior of rodents in the current TUA sug-
gests the opposite; avoidance of the open/lit space is
considered indicative of high anxiety though most, if not
all, authors describe the selection of the protected/unlit
space as a natural preference response. It has been diffi-
cult to challenge this paradox. The anxiety construct
validity of the current TUA is defended on the basis that
these tests involve a conflict, though no objective evidence
has been provided to support the view that animals are
intent on visiting the open/lit space. It is not clear why
the selection and preference of the protected/unlit space
indicates anxiety rather than a sense of safety and secu-
rity. In fact, avoidance and escape responses that termi-
nates the occurrence or experience of an aversive stimulus
is rewarding, and would reinforce the repetition of these
responses (see, Kim et al. 2006). Hence, a mouse or a rat
exposed to EPM, EZP, LDB, or OF escapes to or avoids
from the protected/unlit space, and these responses are
consolidated further with repeated exposures to these tests
(Arabo et al. 2014; Casarrubea et al. 2013; Espejo 1997;
Holmes and Rodgers 1998; Rosa et al. 2000; Treit et al.
1993).
Stretch-attend posture is one of the ethological parame-
ters that is presented as indicative of the conflict experi-
enced by animals in the TUA. Decreased open arm
entries and increased stretch-attend postures are consid-
ered indicative of increased anxiety in the EPM. We argue
here that stretch-attend posture does not provide objec-
tive and unequivocal measures of the ‘hidden motivation’
of animals to explore the open/lit space, and less likely an
indicator of anxiety. In fact, it proved inconsistent and
unreliable in a number of studies. In the EPM, diazepam
was reported to increase the percent open arm entries
(POAE) (Dalvi and Rodgers 1999; Mechan et al. 2002)
and percent open arm time (POAT) (Mechan et al. 2002)
Figure 1. Picture of the three-dimensional 9 arms maze.
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without producing any effect on stretch-attend posture
(Dalvi and Rodgers 1999; Mechan et al. 2002). Gepirone,
a 5-HT partial agonist, was also reported to increase
POAE and POAT without any effect on SAP (Silva and
Brand~ao 2000). In the EZM, both amphetamine and
chlordiazepoxide were reported to increase the amount of
time in the open areas of the maze and decreased the
occurrence of stretched-attend postures (Weiss et al.
1998). This anxiolytic-like effect of amphetamine con-
trasts with the anxiogenic-like effect of this same drug
observed in the EPM in another study in which chronic
treatment with AMPH produced a significant decrease in
POAT and no effect on SAP (Cancela et al. 2001). In
addition, acute treatment with fluoxetine was reported to
decrease POAE and POAT while chronic treatment had
no effect, and both treatments did not affect SAP (Silva
and Brand~ao 2000). The above studies highlight the
inconsistency of the results obtained in the EPM or EZM,
and illustrate the poor utility of stretch-attend posture.
There is no concordance between this ethological parame-
ter and the traditional measures of anxiety.
In the 3D maze, animals that express high anxiety
through avoidance of the arms in the first sessions do visit
the arms after a number of exposures to the test (Enna-
ceur 2011). The motivation to explore the arms is evident
with both low and high anxiety strains as the number of
entries increases, and exceeds 8 arm visits with further
exposures. In the EPM, however, the number of open arm
entries decline to a floor level in a subsequent exposure
whether animals were low or high anxiety strain (Arabo
et al. 2014; Cook et al. 2002; Espejo 1997; Holmes and
Rodgers 1998; Rodgers and Shepherd 1993; Treit et al.
1993), and whether they received saline or anxiolytic treat-
ments (Dawson et al. 1994; Bertoglio and Carobrez 2003;
Escarabajal et al. 2003; File et al. 1992; Holmes and Rod-
gers 1998; Rodgers and Shepherd 1993). These results
from repeated exposures to the EPM underlie furthermore
animals’ lack of motivation to explore the open/lit space.
Single Versus Multiple Test Sessions
One of the major limitations of the EPM is that it cannot
be used for more than one session in screening for poten-
tial anxiolytic candidate drugs. Numerous studies
reported that animals exposed for more than one session
to the EPM demonstrate further avoidance of the open
arms. Benzodiazepines and other drugs proved ineffective
in a second exposure to the test (Bertoglio and Carobrez
2003; Dawson et al. 1994; Escarabajal et al. 2003; File
et al. 1992; Holmes and Rodgers 1998; Rodgers and Shep-
herd 1993).This lack of sensitivity makes it very difficult
to predict the therapeutic potential of a drug, especially
for chronic use, as it is possible that an initial reaction to
a drug differs from its effects on subsequent uses
(Abuhamdah et al. 2015; Cole and Pieper 1973; de Wit
and Phillips 2012).
When exposed to an unfamiliar radial arm maze, rats
and mice enter frequently into the proximal segment of an
arm of the maze and do not continue into the distal seg-
ment. In the 3D maze, these proximal (bridges) and distal
(arms) segments are clearly delineated. Animals are
observed to reach the end of the first segment, then with-
draw and return to the central platform. They seem unable
to take a risk and venture far away from the central plat-
form. This avoidance of the distal segment is used as an
indicator of fear and anxiety in mice. In previous studies
(Ennaceur et al. 2006, 2008; Ennaceur 2011), we demon-
strated that BALB/c mice, unlike C57BL/6J and CD-1
mice, did not venture into the arms of the maze when left
to explore for the first time. C57BL/6J and CD-1 mice vis-
ited a number of arms on the first and second exposure,
respectively, whereas BALB/c required more exposures
(Fig. 3). Hence, unlike in the EPM and the other anxiety
tests, in which subsequent exposures lead to a reduction in
motor activity and further avoidance of the open/lit space
in both anxious and nonanxious strains of mice, in the 3D
maze there is no decrease in motor activity but there is
rather a decrease in avoidance responses. When a mouse
starts visiting an arm or a few arms in a session, it contin-
ues visiting more arms in subsequent sessions (i.e.,
becomes less anxious with experience).
The 3D maze anxiety test can be run in a single 10–
12 min session, or in multiple sessions with or without
food deprivation. Repeated visits, each initiated from the
central platform, to the same arms are counted as sepa-
rate individual visits whereas repeated back and forth
visits between a bridge and an arm are counted as a single
visit. It is possible to set a criterion of 8 or 9 arm visits in
a session that lasts 10–12 min. BALB/c mice reached this
criterion in five sessions, whereas C57 and CD-1 required
1 to 2 sessions, respectively (Fig. 3). Consistent differences
were observed between these three strains of mice in a
number of experiments conducted in our laboratory.
The 3D maze offers a large window of opportunity to
observe the effects of an experimental manipulation on
anxiety. Using a high anxiety strain, the effect of an anxi-
olytic drug can be detected within a few number of ses-
sions, whereas using a low anxiety strain an anxiogenic
effect can be detected in the first session and can last over
a number of sessions.
Anxiety Indices and Measurements
The TUA are further complicated by the availability of a
variety of spatio-temporal and ethological parameters,
among which only a few and sometimes a single parame-
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ter (not always the same one) is reported to indicate a
change in anxiety response (Crawley and Davis 1982;
Drapier et al. 2007; Ducottet and Belzung 2004, 2005;
Kulesskaya and V~oikar 2014; Lalonde and Strazielle 2008;
Lin et al. 1999; Rodgers et al. 2002a,b; V~oikar et al.
2004). In addition, in the EPM, the majority of authors
prefer reporting percent instead of absolute values (Daw-
son et al. 1995; Silva and Branda˜o 2000; Rodgers et al.
2002a) while it is apparent that, in some cases, differences
between strains or drug treatment and doses are observed
in animals with low exploratory activity and/or with a
small difference between open arm and enclosed arm
entries. In addition, POAT is obtained from time spent in
the open arms divided by test duration (Rodgers et al.
1997, 2002a,b; Dalvi and Rodgers 1999; Jones and King
2001; Mathiasen et al. 2008) or time spent divided by the
total time spent in both arms (Bertoglio and Carobrez
2002; Lin et al. 1999; Fernandes and File 1996; Trullas
and Skolnick 1993). The former includes a significant
amount of time spent in the central area of the maze.
In the EPM, changes in anxiety are often determined
by one selected index, and in most cases it is the time
spent in the open arms or POAT (Cook et al. 2001; Hen-
drie et al. 1997; Harada et al. 2006; Heredia et al. 2012;
Rodgers and Dalvi 1997; Wilson et al. 2004; Popik et al.
2006). However, a large amount of time spent in open
arms can sometimes refer to a single or very few open
arm entries. In addition, a mouse strain is determined as
low or high anxiety irrespective of the number of entries
and amount of time spent in open arms, which are often
below 50% of the total entries or the total test duration
(Chaouloff et al. 1997; Dalvi and Rodgers 1999, 2001;
Griebel et al. 2000; Hagenbuch et al. 2006; Harada et al.
2006; Mechan et al. 2002; Menard and Treit 1996;
O’Leary et al. 2013; Rodgers et al. 1997; Shepherd et al.
1994). There is no criterion that determines when avoid-
ance of open arms ceases to be avoidance. A place prefer-
ence parameter can be derived from the difference
between open and closed arm entries or time, but we are
not aware that it has ever been exploited. However,
whichever the selected anxiety parameter, most studies
were unable to demonstrate any concordance between
measurements (File et al. 1998; Harada et al. 2006;
Mathiasen et al. 2008; O’Leary et al. 2013; Rodgers et al.
2002a; Smith et al. 2012; see Table 2). Hence, there is
not a single measure of anxiety that is commonly used to
account for changes in rodents’ anxiety response, and that
one can rely on to compare anxiety test results between
research studies (see Tables 1 and 2). Looking at the first
four rows in table 1, DIFF (preference index) suggests
that the strains of mice in the first and second row are
less anxious than the two strains from the rows below,
whereas the POAE suggests that strains of mice in the
first and third row are the least anxious. However, POAT
suggests that mice on the second row are less anxious
than all other strains, and those in the fourth row are the
most anxious. It is also possible to argue that mice with
90% open time show either strong preference for the
open arms or strong avoidance of the closed arms.
The use of open arms avoidance index (OAAI = 100–
(% time + % entries in the open arms) / 2) proposed by
Trullas and Skolnick (1993) can complicate the matter
further. O’Leary et al. (2013) reported that POAE and
POAT were significantly high in BALB/cBy compared to
all other mouse strains, except BALB/cJ and C3H on
POAE; these two mouse strains were not different from
each other. POAE and POAT were also significantly high
in BALB/cJ compared to AKR and BTBR. However, the
OAAI, which has been used by this group in other studies
(Brown et al. 1999; Podhorna and Brown 2002) seems
low in A/J mice compared to any other mouse strain, and
it seems high in BALB/cJ compared to BALB/cBy and
C3H mice. There were no differences between BALB/cJ
mice and AKR, BTBR or SJL mice. Based on this index,
one can reach a different conclusion from that reported
by the authors. Contrary to POAE and POAT, this index
suggests that A/J is the least anxious mice and not BALB/
cBy mice, and that BALB/cJ mice are more anxious than
BALB/cBy and C3H mice, and they are not less anxious
than AKR, BTBR or SJL mice.
In the 3D maze, a number of parameters are recorded
such as latency of first crossing into a bridge and an arm,
number of crossings and time spent on the bridges and
arms, but only the number of crossings into the arms is
used as the main index of anxiety. In addition, a criterion
of 8 or 9 arm visits in a session that lasts 10–12 min is
used to determine differences in anxiety between mouse
strains and between treatments. Mice that achieve the cri-
terion earlier than others are deemed to present low level
of anxiety. The latency of first entry onto an arm is
another specific index of anxiety, but it can be influenced
by the handling expertise of the experimenter. We recom-
mend that a small beaker is used to transport a mouse to
the maze. The beaker is then tilted gently over the floor of
the central platform to release a mouse.
It has been suggested that risk-avoidant decision mak-
ing is specifically associated to anxiety (Maner et al. 2007;
Giorgetta et al. 2012; Paulus and Yu 2012). This behavior
implies that, in anxiety situation, there is a time spent to
evaluate a risk, which may or may not be followed by the
execution of a risky decision. Hence, the time it takes to
approach a threatening stimulus (latency) and the num-
ber of approaches of this stimulus can be used as specific
measures of anxiety. However, it is not possible to rely
on the latency to approach as well as the time spent in
contact with the threatening stimulus unless more than a
2016 | Vol. 4 | Iss. 2 | e00223
Page 18
ª 2016 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
Preclinical Anxiety Research Methodology A. Ennaceur & P. L. Chazot
single approach is recorded, for a mouse or a rat may
approach and spend a long time in contact with a poten-
tially threatening stimulus then demonstrates a systematic
avoidance response afterward. For instance, a mouse can
run into an arm and freezes there. This mouse may
record longer time than a mouse that moved freely in the
maze and recorded a high number of arm entries. We
observed this behavior with some C3H mice, which did
not differ significantly from CD-1 in the time spent in
the arms (see Fig. 2). However, C3H mice did not visit
more than one arm, whereas CD-1 mice made at least
three arm visits each.
It is important to note here that, in the 3D maze, non-
specific effects of a treatment are determined from entries
and time spent on the bridges. Strictly, a treatment is
deemed anxiolytic if a high anxiety strain makes at least 8
arm visits, and that arm/bridge entries ratio approaches 1.
A treatment is deemed anxiogenic if a low anxiety strain
of mice demonstrates a reduction in the number of arm
entries and the index arm bridge ratio is inferior to 50%.
The reduction in arm entries must be below the mini-
mum 8 arm visits.
Among the most commonly used mouse strains in
anxiety studies, C3H/J, CBA/J, FVB/NJ, and SJL/J have
been reported to present retinal degeneration (Mro-
sovsky et al. 1999; Chang et al. 2002; Clapcote et al.
2005). Inconsistencies between reports do not allow us
determine whether such handicap could account for
differences in anxiety response between any of these
and other strains of mice in TUA. These inconsistencies
are not limited to anxiety indices but extend to loco-
motor and exploratory activity as well. Each of these
mouse strains has been shown to demonstrate either
high or low anxiety in different reports (Table 2). In a
number of studies, C3H mice appear to spend longer
time in the open arms (expressed in percent) than
some other mouse strains (Brooks et al. 2005; Cook
et al. 2001; Griebel et al. 2000; Hagenbuch et al. 2006;
Lad et al. 2010; O’Leary et al. 2013). These studies did
not indicate whether these visits were limited to the
proximal or distal segments of the open arms, and
some authors did not disclose the actual number of
entries into the open or enclosed arms. In the 3D
maze, C3H mice appear to differ from all other mouse
strains by their low number of bridge entries
(8.23  2.04). This is not the case with CBA mice,
which suffer from the same retinal degeneration. The
number of crossings in CBA (22.13  2.16) was not
different from that of BALB/c (18.31  2.31) and DBA
(20.25  3.24). In the present experiment, C3H mice
appear to demonstrate high anxiety comparable to that
of BALB/c, CBA, and DBA mice. They may require a
number of exposures to the test to make eight or more
arm visits as it was demonstrated in BALB/c mice.
Sensitivity of the 3D Maze to Strains
of Mice and Drug Treatments
Strains of mice
Assessment of the effects of an experimental intervention
requires either the selection of a strain of rats or mice
that allows bidirectional changes in anxiety responses, or
the selection of two strains of rats or mice that show
Figure 2. In this experiment, different strains of mice were exposed to 8 arms maze in a single 12 min session. (A) The number of crossings into
the bridges was significantly high in C57 and CD1 mice and significantly low in C3H mice compared to the other strains of mice. BALB/c, C3H,
CBA/J, and DBA mice made generally no entries into the arms (80% made zero visits), whereas C57 and CD1 mice did cross into the arms with a
group average of 12 and 5 arm visits, respectively. (B) The time spent on the arms is significantly high in C57 mice compared to the other
groups. The time spent by C3H on the arms represents a single arm visit made by half of the group, the other half made no visit.
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opposite anxiety responses. In the latter, an anxiolytic
treatment will be expected to bring the level of high anxi-
ety strain (experimental) close to that of the low anxiety
strain (control) and an anxiogenic treatment will increase
anxiety to the level of the high anxiety strain (control).
We examined a number of mouse strains for differ-
ences in response to exposure to the 3D maze in a single
12 min test sessions. These strains comprise five inbred
strains (BALB/cByJ, C3H/HeJ, C57BL/6J, CBA/J, DBA/2J),
and one outbred strain (CD1-ICR). We did also examine
difference between BALB/cByJ, C57BL/6J, and CD1-ICR
mice in three or more test sessions; these are either food
or nonfood deprived. The single test session study indi-
cated that BALB/c, C3H, CBA/J, and DBA mice made
generally no entries into the arms (80% made 0 visit),
whereas C57 and CD1 mice did cross into the arms with
a group average of 12 and 5 arm visits, respectively
(Fig. 2). This study indicates that C57 and CD-1 pre-
sented a low level of anxiety compared to the other
strains of mice. However, if we introduce 8-arm visits cri-
terion, then only C57 qualifies as a low anxiety strain.
This criterion is necessary to determine when animals are
no longer avoiding the arms. Its relevance is more evident
when animals are exposed to the test for more than a sin-
gle session.
In a multiple test sessions, we examined the behavior
of food deprived BALB/c, C57, and CD-1 mice, and we
observed that BALB/c mice required about five sessions to
make 8 arm visits, whereas C57 and CD1 mice made this
number of arm visits after one or two sessions, respec-
tively (Fig. 3). C57BL/6J mice treated with dizocilpine, an
NMDA receptor antagonist, demonstrated an increase in
anxiety which was maintained over more than seven ses-
sions (Ennaceur et al. 2011). These mice made more
bridge entries than saline-treated mice, which preclude
psychomotor deficits (see section Anxiety indices and
measurements).
We explored food deprivation because this was
reported to increase exploratory activity (Carr et al. 1959;
De Lorge and Bolles 1961; File and Day 1972; Timberlake
and Birch 1967; Levay et al. 2007) and affect anxiety
responses (Levay et al. 2007; Inoue et al. 2004; Jahng
et al. 2007) in rodents. In addition, anxiety as well as
both anxiolytic and anxiogenic interventions can affect
learning and memory performance (Macbeth and Luine
2010; Mintzer and Griffiths 2007; Nakamura–Palacios and
Roelke 1997; Ohl et al. 2003; Packard 2009; Salomons
et al. 2012). Screening for novel anxiolytics needs to
exclude any deleterious drug effect on cognition. For
instance, benzodiazepines’ anxiolytic effect is undermined
by its negative action on some cognitive processes (Coull
et al. 1995; Herzog et al. 2000; Mintzer and Griffiths
2007; Nakamura–Palacios and Roelke 1997; Soto et al.
2013; Tiplady et al. 2005).
It has been suggested to us that such differences
between strains have been demonstrated with the current
TUA, and therefore the present 3D maze open space anxi-
ety test does not provide anything new. Indeed, numerous
studies investigated the behavior of various strains of
mice in the current TUA, and over 30 years since these
tests were proposed, there is not a single strain of mice
that is consistently reported to present either low or high
anxiety within the same anxiety test or between anxiety
tests (Cook et al. 2001; DuBois et al. 2006; Griebel et al.
Figure 3. In this experiment, mice were food deprived, and exposed to 8 arms maze until 8 arm visits were made or 10 min elapsed. (A) C57
made 8 arm choices with a high number of bridge visits; it was followed by CD-1 on the third sessions and BALB/c in the fifth session. (B) With
repeated exposures to the maze, the number of bridge visits decreased until arm/bridge entries ratio got close to 1. The arm/bridge ratio is over
0.6 in the third session for C57 and CD1 mice and in the fifth session for BALB/c mice.
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2000; Holmes et al. 2002; Livneh et al. 2010; Podhorna
and Brown 2002; V~oikar et al. 2005).
BALB/c and C57BL/6 mice are the most commonly
used in anxiety studies. Some studies reported that the
former are more anxious than the latter in the LDB
(Kopp et al. 1999; Lepicard et al. 2000; Griebel et al.
2000; Verleye et al. 2011) and in the EPM (Lepicard et al.
2000; Verleye et al. 2011), whereas other studies demon-
strated lower anxiety in BALB/c mice in the EPM (An
et al. 2011; Avgustinovich et al. 2000; Griebel et al. 2000;
Livneh et al. 2010; Nesher et al. 2012; Trullas and Skol-
nick 1993) or no difference between the two mouse
strains in the EPM (Brooks et al. 2005; Griebel et al.
2000; Lalonde and Strazielle 2008; Keum et al. 2016; Yil-
mazer–Hanke et al. 2003), the OF (Keum et al. 2016;
Kim et al. 2002) and the LDB (Kim et al. 2002).
Inconsistent reports were observed in other strains of
mice. For instance, DBA/2 mice were reported to present
high anxiety in the OF (DuBois et al. 2006; Holmes et al.
2002; Lad et al. 2010) and the LDB (V~oikar et al. 2005;
DuBois et al. 2006; Holmes et al. 2002; Lad et al. 2010)
compared to C57 mice, and in the EPM compared to
C57 (Lad et al. 2010; V~oikar et al. 2005) and BALB/c
mice (Rogers et al. 1999). They were also reported to pre-
sent low anxiety compared to C57 in the EPM (Gard
et al. 2001; Podhorna and Brown 2002; Trullas and Skol-
nick 1993) and the OF (Podhorna and Brown 2002; Trul-
las and Skolnick 1993). Other results indicate no
differences between DBA and C57 in the LDB (Gard et al.
2001; Griebel et al. 2000) and in the EPM (Brooks et al.
2005; Griebel et al. 2000; Holmes et al. 2002).
Additional examples of inconsistencies are observed in
C3H mice. This strain of mice was reported to display
low anxiety in the EPM compared to DBA, C57 (Brooks
et al. 2005; Cook et al. 2001; Griebel et al. 2000; Trullas
and Skolnick 1993; Livneh et al. 2010) and BALB/c
(Brooks et al. 2005; Cook et al. 2001; Griebel et al. 2000).
It was also shown to display low anxiety in the LDB com-
pared to BALB/c (Bouwknecht and Paylor 2002; Griebel
et al. 2000; Kopp et al. 1999; Lad et al. 2010), and in an
OF compared to BALB/c and C57 (Kopp et al. 1999; Lad
et al. 2010). However, other studies reported that C3H
display high anxiety compared to BALB/c in the EPM
(Rogers et al. 1999; Trullas and Skolnick 1993; Yilmazer–
Hanke et al. 2003) and compared to C57 in the EPM
(Yilmazer–Hanke et al. 2003) and EZM (Tarantino et al.
2000; Wilking et al. 2012). They were also reported to
display high anxiety compared to BALB/c and C57 in the
LDB (Kopp et al. 1999). In contrast, other studies
reported no difference between C3H and C57 (Ducottet
and Belzung 2005; Hagenbuch et al. 2006) and between
C3H and both DBA and BALB/c in the EPM (Ducottet
and Belzung 2005; Griebel et al. 200; Lad et al. 2010), the
LDB (Bouwknecht and Paylor 2002; Griebel et al. 2000;
Lad et al. 2010) and the OF (Lad et al. 2010).
Comparable inconsistent and conflicting results have
been reported in various publications, but their authors
fell short to question the construct validity of the TUA.
They suggested instead various contributing factors.
These include animal suppliers (Parra et al. 2013; Palm
et al. 2011), the handling experimenter (Heredia et al.
2012; Crabbe et al. 1999; Lewejohann et al. 2006; Chesler
et al. 2002), apparatus structure and color (Fernandes
and File 1996; Violle et al. 2009; Horii and Kawaguchi
2015; Filgueiras et al. 2014; Albrechet–Souza et al. 2005;
Lamberty and Gower 1996), or illumination and light/
dark cycle (Fonken et al. 2009; Violle et al. 2009; Garcia
et al. 2005), cage color (Sherwin and Glen 2003) and
cage group size (Heredia et al. 2012; Botelho et al.
2007), enrichment (Abramov et al. 2008; Loss et al.
2015; Ravenelle et al. 2014), and bottle drinking size ori-
fice (Dotson and Spector 2005). In fact, anything from
the laboratory environment, even an allergic experi-
menter wearing a respirator (Crabbe et al. 1999), has
been presented to justify the appalling state of affairs of
the TUA. While evidence in support of the contribution
of a number of these factors has been provided, subse-
quent reports appear to contradict these lines of evidence
(Goes et al. 2015; Jones and King 2001; Arndt et al.
2009; Augustsson et al. 2003; Becker and Grecksch 1996;
Nicholson et al. 2009; Hagenbuch et al. 2006; Cohen
et al. 2001; Lewejohann et al. 2006; Pellow et al. 1985;
Wolfer et al. 2004).
Diazepam
Diazepam, chlordiazepoxide, and other benzodiazepine
drugs have been reported to demonstrate anxiolytic effects
in the EPM, the LDB and the OF (Chaouloff et al. 1997;
Costall et al. 1989; Crawley 1985; Crawley and Goodwin
1980; Pellow et al. 1985; Lepicard et al. 2000; Hasco€et
and Bourin 1998; Mechan et al. 2002). This sensitivity to
the anxiolytic effects of benzodiazepines seems to vary
between strains of mice, and between anxiety tests, and it
is neither with the same strain of mice nor with the same
anxiety test between reports (Belzung et al. 2000; Crabbe
et al. 1999; Griebel et al. 2000; Rodgers et al. 2002a;
Mechan et al. 2002; Lepicard et al. 2000; Hasco€et and
Bourin 1998). In addition, prior experience was found to
abolish the effect of benzodiazepines on anxiety indices
(Bertoglio and Carobrez 2002; Cruz–Morales et al. 2002;
Dawson et al. 1994; File and Zangrossi 1993; Holmes
et al. 2001; Rodgers and Shepherd 1993; Treit et al.
1993).
In the 3D maze, we examined the effect of different
doses of diazepam in BALB/c, C57BL/6J, and CD-1
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(Ennaceur et al. 2008). The results did not produce the
expected anxiolytic effects in BALB/c mice, but demon-
strated rather a dose-dependent decrease in the number
of bridge and arm visits in C57BL6/J mice. The number
of bridge and arm entries was also decreased in CD-1 and
appears unaffected in BALB/c mice (Fig. 4). The effect of
diazepam in the 3D maze contrasts with results obtained
with the same doses in another open space anxiety test,
the elevated platform with steep slopes attached on two
opposite sides (Ennaceur et al. 2010). In this test, all
BALB/c mice that were injected with different doses of
diazepam were able to cross into the slopes from the first
test session, and continued to do so in subsequent two
sessions, whereas BALB/c mice that were injected with sal-
ine or different doses of amphetamine remained on the
platform. The effects diazepam in the 3D maze can be
accounted for its impairing effects on some cognitive
functions, and in particular spatial working memory,
which are not necessary in the elevated platform (Coull
et al. 1995; Herzog et al. 2000; Nakamura–Palacios and
Roelke 1997; Soto et al. 2013; Tiplady et al. 2005). The
choice of a slope in the elevated platform is less cogni-
tively challenging than the choice between eight or nine
arms of a radial maze. Hence, one would predict that an
anxiolytic drug that has no impairing effect on cognition
would facilitate crossings into the arms of the 3D-maze.
Fluoxetine
Animal studies demonstrated mixed results with the use
of SSRIs on anxiety. Some studies reported anxiogenic
effect with acute (Birkett et al. 2011; Drapier et al. 2007;
Gomes et al. 2009; Kurt et al. 2000; Robert et al. 2011;
Silva et al. 1999; Silva and Brand~ao 2000) and anxiolytic
effect with chronic (Gomes et al. 2009; Kurt et al. 2000;
Nowakowska et al. 2000) treatments, whereas other stud-
ies reported anxiolytic (Griebel et al. 1999; Nowakowska
et al. 1996, 2000; Rogoz and Skuza 2011) or no effect
(Durand et al. 1999; Knoll et al. 2007; Takeuchi et al.
2010) with acute treatments. Some studies reported also
anxiogenic (Robert et al. 2011; Silva et al. 1999) or no
effect (Durand et al. 1999; Silva and Brand~ao 2000; Grie-
bel et al. 1999; Takeuchi et al. 2010) with chronic treat-
ments. These conflicting results were mostly obtained in
TUA which have been reported to produce inconsistent
results with a wide range of psychoactive compounds
(Cryan and Sweeney 2011; Griebel and Holmes 2013;
Miczek and de Wit 2008; Rodgers et al. 1995, 2002a;
Thompson et al. 2015). One of the major limitations of
these tests, mentioned earlier, is that they cannot be used
for more than one session in screening for potential anxi-
olytic candidate drugs. In addition, examination of the
effect of SSRIs on anxiety involves administration of the
drugs for several days; this implies that animals are
repeatedly handled when drugs are given by direct admin-
istration. This manipulation could affect animal response
to the anxiety test as reported in a number of studies
(Andrews and File 1993; Brett and Pratt 1990; Robert
et al. 2011; Schmitt and Hiemke 1998).
In a recent study (Abuhamdah et al. 2015), we used
the 3D maze to assess the effects of fluoxetine (20 mg/kg,
i.p.) on anxiety in BALB/c mice. We examined whether
the anxiolytic effects of fluoxetine can be detected over
three test sessions. We examined also, whether repeated
handling associated with a chronic treatment interferes
with the effects of fluoxetine on anxiety responses. Two
separate groups received once a day either saline (S
chronic) or fluoxetine (F chronic) for 14 days, and con-
Figure 4. In this experiment, different strains of mice (c57BL/6J, CD-1 and BALB/c) were introduced to 8 arms maze, and left to explore for
12 min. Each strain of mice was constituted of four groups, each receiving either saline or a single injection of one dose of diazepam 30 min before
the test. Diazepam had no effect on BALB/c mice but significantly decreased the number of bridge (A) and arm (B) entries in C57 and CD-1 mice.
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tinued to be injected before the test during the subse-
quent 3 days. The third group received saline (S acute)
before the test, once a day for 3 days. Saline-acute-trea-
ted mice did not cross into the arms, and continued to
do so over three sessions. Saline-chronic-treated mice
avoided the arms in session 1, whereas fluoxetine-
chronic-treated mice did cross into the arms. In subse-
quent sessions, the number of crossings into and time
spent in the arms increased in these two chronic treated
groups (Fig. 5). Fluoxetine appears to have produced an
anxiolytic effect but this was evident only in the first ses-
sion. These results suggest that repeated handling experi-
ence during the chronic treatment period did affect
anxiety responses; it decreased fear and anxiety in mice,
and this may have masked the anxiolytic effect of fluox-
etine in the second and third test sessions. Handling
experience, however, did not prevent an initial sponta-
neous anxiety response in chronic-saline-treated mice.
Exposure to novelty (3D maze) appears to facilitate the
“return of fear” which can be accounted for by the disha-
bituation phenomenon (Rachman 1989; Thompson and
Spencer 1966).
Dizocilpine
A number of studies suggest that NMDA antagonists may
have potential anxiolytic properties (Criswell et al. 1994;
Dunn et al. 1989; Engin et al. 2009; Wieronska et al.
2003; see, Cryan and Dev 2008). However, their anxiolytic
effects is subject to conflicting reports (Criswell et al.
1994; Mansbach et al. 1991; Sanger and Joly 1991; Solati
2011; Solati and Salari 2011; Yagi et al. 1998). NMDA
antagonists were reported to induce hyperactivity (Bard-
gett et al. 2003; Carey et al. 1998; Hargreaves and Cain
1992; Martin et al. 1997; Whishaw and Auer 1989). This
hyperactivity is a confounding factor in the current ani-
mal tests of anxiety (Dawson and Tricklebank 1995; Daw-
son et al. 1995). Hence, in some studies their apparent
anxiolytic effect was attributed to drug-induced hyperac-
tivity (Wiley et al. 1995), whereas in other studies hyper-
activity was observed without evidence of reduced anxiety
(Bardgett et al. 2003; Criswell et al. 1994; Mansbach et al.
1991; Sanger and Joly 1991; Silvestre et al. 1997). Further-
more, in spatial navigation tasks, familiarization with the
test environment appears to prevent the impairing effects
of NMDA antagonists on learning and memory (Cain
1997; Caramanos and Shapiro 1994; Roesler and Vianna
1998; Saucier et al. 1996; Saucier and Cain 1995; Shapiro
and O’Connor 1992). This familiarization effect raised the
issue of whether NMDA receptor antagonists do increase
anxiety, which is confounded with learning and memory
performance, particularly in a stressful environment such
as in the water maze.
In a previous study (Ennaceur et al. 2011) conducted
in the 3D maze, mice treated with dizocilpine, demon-
strated avoidance of the arms despite a significant large
increase in bridge entries. This translated to impaired
acquisition of a working memory task. We suggested that
this impairment could be due to dizocilpine producing
an increased and sustained anxiety. In a recent study, we
Figure 5. BALB/c mice were introduced to 9 arms maze and left to explore for 12 min in each test session. Number of entries into and time
spent on bridges (B) and arms (A). Two separate groups received once a day either saline (S chronic, n = 8) or fluoxetine (F chronic, n = 8) for
14 days, and up to 30 min before the test during the subsequent 3 days. A third group received saline (S acute, n = 8) 30 min before the test,
once a day for 3 days. (A) S acute mice did not cross into the arms in the three test sessions, whereas S chronic mice did cross into the arms in
sessions 2 and 3. F chronic did cross into the arms in all three sessions. The arm/bridge entries ratio in session 3 was 0.02  0.1 for S acute,
0.70  0.1 for S chronic and 0.50  0.1 for F chronic. (B) The arm/bridge duration ratio in session 3 was 0.01  0.01 for S acute, 2.81  0.56
for S chronic and 1.54  0.43 for F chronic.
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examined whether, in pretrained mice, dizocilpine will
still produce increased anxiety. C57BL/6J mice, which dis-
play low anxiety in the 3D maze, were treated with saline
or dizocilpine (0.1 mg/kg i.p.) and exposed to the maze
in seven consecutive sessions, one session per day. The
experiment involved three groups of mice. One group
received a single daily injection of saline (SAL d1),
whereas a second group received a single daily injection
of dizocilpine (DIZ d1). A third group (DIZ d4) received
saline in the first three sessions and dizocilpine in each
subsequent session. All saline-treated mice made numer-
ous visits to the arms, whereas mice treated with dizocil-
pine for 7 days showed reduced entry onto the arms.
Dizocilpine had no effect on arm entries in mice treated
on the fourth day onward. These mice demonstrated
instead a steady large increase in the number of bridge
(Fig. 6A) and arm (Fig. 6B) entries, which suggests
impaired habituation to the test environment. It pro-
duced sustained nonhabituating hyperactivity; a phe-
nomenon that have been reported for NMDA receptor
antagonists (Klamer et al. 2004; Reus et al. 2008; Vena^n-
cio et al. 2011) and genetic models of NMDA hypo-func-
tion (Ballard et al. 2002; Bickel et al. 2008; Duncan et al.
2006). Mice treated with saline from day 1 and those
treated with dizocilpine from day 4 reached a bridge/arm
entries ratio superior to 0.9 in session 5 (Fig. 6C) which
indicates that they were moving from bridges to arms
without hesitations.
Figure 6. C57BL/6J mice were introduced to 9 arms maze, and left to explore for 10 min in each test session. The experiment consists of three
groups of C57BL/6J mice, which received a single daily injection of either saline or dizocilpine 30 min before the test. The first group received
saline each test day (SAL d1). The second group received saline on day 1 to 3, then dizocilpine from day 4 (DIZ d4). The third group received
dizocilpine each day (DIZ d1). The results of BALB/c saline-treated mice were part of a separate experiment. They are included here for illustration
only. (A) Dizocilpine increased the number of bridge entries in DIZ d1 and DIZ d4 groups compared to SAL d1 group. (B) the number of arm
entries was decreased in DIZ d1 group and increased in DIZ d4 group; (C) Arm/bridge entries ratio was significantly low in DIZ d1 group
compared to SAL d1 group and DIZ d4 group; the latter two were not different from each other.
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Dizocilpine and other NMDA antagonists have been
reported to increase locomotor activity and impulsive
response (Amitai and Markou 2010; Higgins et al. 2003;
Scott and Taylor 2014; Smith et al. 2012). In the 3D
maze, unlike in the TUA, the psychomotor-stimulating
effect of a drug is detected by the number of bridge
entries and cannot be confounded with anxiolysis, which
is detected, by the number of arm entries. In DIZ d1
mice, the increase in bridge entries, though not as high as
in DIZ d4 mice, was opposed by a high level of anxiety,
which prevented mice from crossing onto the arms. This
behavior compares to that observed with amphetamine in
another open space anxiety test, the elevated platform
with steep slopes attached on two opposite sides (Enna-
ceur et al. 2010). Amphetamine produced a dose-depen-
dent hyperactivity in BALB/c mice without producing a
single crossing onto a slope. In DIZ d4 mice, the psy-
chomotor-stimulating effect of dizocilpine may account
for the high number of crossings into the arms. However,
these mice had a low basal level of anxiety at the start of
the test – a low anxiety strain, and prior experience with
the maze and saline injection. It remains unlikely that
such level of anxiety could be decreased further. However,
this psychomotor stimulation may have impaired habitua-
tion as these mice demonstrated concurrent increase in
bridge and arm entries after each exposure to the maze.
NMDA antagonists have been reported to impair habitua-
tion in various behavioral tests (Ballard et al. 2002; Bickel
et al. 2008; Duncan et al. 2006; Klamer et al. 2004; Reus
et al. 2008; Rosat et al. 1992; Vena^ncio et al. 2011). The
present results suggest that dizocilpine exacerbates anxi-
ety; this contrasts with results obtained with dizocilpine
and other NMDA antagonists in the EPM which sug-
gested an anxiolytic effect (Bertoglio and Carobrez 2003;
Bergink et al. 2004; Dunn et al. 1989; Wiley et al. 1995).
However, NMDA antagonists increased locomotor activ-
ity, which is a confounding factor in the determination of
the anxiolytic effect of drug treatments in the EPM. In
the 3D maze, an increase in motor activity or hyperactiv-
ity in high anxiety mice does not facilitate crossing into
the arms and remains limited to the bridges. As indicated
above, dizocilpine-treated mice made more crossings into
the bridges than saline-treated mice but they were unable
to cross into the arms in the first three sessions; their
number of arm entries remained significantly low in sub-
sequent sessions compared to saline-treated mice.
The ability to test animals for a number of sessions is
an important advantage over the EPM and other TUA. In
the latter, exploratory and locomotor activities decrease
significantly and approach a floor level in subsequent
exposures. This decrease is associated with habituation
(Cook et al. 2002; Dawson et al. 1994; Espejo 1997;
Holmes and Rodgers 1998; Treit et al. 1993) but it cannot
be discriminated from an increase in anxiety, and it is
observed in both high and low anxiety mouse and rat
strains. In the 3D maze, high anxiety is observed in some
mouse strains, and this does decrease in subsequent expo-
sures to the test. This corresponds to what is generally
expected in normal human subjects as well as in animals.
High anxiety mouse and rat strains do not represent a
model of pathological anxiety. They represent differences
between individuals or group of individuals in coping
strategies with threat and stress. In the 3D maze, both
high and low anxiety mice demonstrate an increase in
arm entries with repeated exposures, and this could be
due to habituation. Therefore, it is expected that animal
models of anxiety produced with drugs, lesions or genetic
manipulations will demonstrate reduced or delayed
habituation, and may remain unable to reach the crite-
rion of a minimum 8 arm visits, and arm bridge entries
ratio close to 1.
The present results suggest that dizocilpine exacerbates
anxiety. It remains to be demonstrated whether, a compa-
rable or an opposite effect, is observed with BALB/c mice,
a high anxiety strain, and whether an anxiogenic interven-
tion would affect habituation and anxiety response.
Conclusion
In summary, the current TUA suffer from a major initial
flaw in their conception, which has been overlooked and
complicated over at least 3 decades by subsequent phar-
macological validation. The flaw resides in the fact that
animals demonstrate escape to or avoidance from the
protected and/or unlit space of these test apparatus.
While one may view that an open space evokes anxiety in
mice and rats, though it is apparent that generally these
rodents did not explore these spaces, another may view
either that animals avoided the unprotected/lit space,
hence diminishing or terminating the fear response, or
that they demonstrated a natural preference for the pro-
tected/unlit space which promotes a feeling of safety and
security. These equivocal interpretations of the same
behavioral response undermine entirely the validity of the
TUA.
The TUA validity is further undermined by the diver-
sity and inconsistencies of their measurements. Up to
date, there is not a single index, commonly agreed upon,
which provides a specific and/or reliable measure of anxi-
ety. Number of crossings, time spent, percent number,
and percent time in the unprotected/lit space are rarely
concordant (Table 1). Anxiety is determined, in most
cases, by a change to any one of these measurements. The
same is true for measurement of locomotor activity,
which is represented by either the number of crossings or
distance travelled. In the EPM, locomotor activity is also
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represented by the total number of crossings into all arms
in some reports, and by the number of crossings into the
enclosed arms in other reports. Furthermore, measure-
ments of anxiety and locomotor activity appear to be
determined a-posteriori. Hence, only one measurement or
a subset of measurements are selected and reported in a
particular study (Table 2). These measurements vary
between studies, which explain their diversity and the dif-
ficulty to compare between research reports (Table 2). In
addition, the lack of reliability of the primary indices of
anxiety (open entries, open time and percent of these
two, see Table 1) promoted a desperate need for other
types and forms of measurements; these contributed to
further diversity and complexity. In some studies, spatio-
temporal parameters were either complemented or sup-
planted with ethological parameters, whereas in other
studies either one of these is selected as it seems fit.
It has been pointed out over the years that the current
TUA suffer major limitations, which concern the design
of the test conditions and test parameters. Various sug-
gestions have been proposed and numerous attempts have
been made to circumvent these limitations, but there is
yet no evidence demonstrating any improvement in the
reliability and consistency of the results obtained in these
tests. As argued in this, and in a previous report (Enna-
ceur 2014), the current TUA do not provide unequivocal
measures of anxiety; these are sine qua non for the valid-
ity of a behavioral test. This primary concern cannot be
resolved with some modifications to the layouts of the
test apparatus or some changes to the test procedures.
There is an urgent need for a complete radical overhaul
approach for the development of behavioral assays of
anxiety in animal research. Such behavioral assays need to
demonstrate that the measured construct, anxiety, is
unequivocally discriminated from measures of other con-
structs that it may be confounded with, such as fear-
induced avoidance or escape. To achieve this, a novel test
of anxiety needs to expose animals to an aversive situa-
tion, which involves uninformative or ambiguous stimuli,
and that the outcomes from the choice between these
stimuli are uncertain. Hence, an unfamiliar open space,
such as the 3D maze, can provide an aversive situation
that evokes fear, which motivates escape and avoidance
responses of threatening situations. In anxiety conditions,
fear cannot be diminished or terminated by an escape or
an avoidance response. This is simply because fear is gen-
eralized to the entire situation that evoked such fear.
Unlike in the current TUA, any part of the test situation
can be perceived as a source of threat. Animals will try to
escape the whole situation if possible but to do so they
must explore to find out whether there is an escape route.
This escape response has been used to determine anxiety
in animals. Our studies demonstrate that some mice do
not cross into the distal segments of the mazes, hence
they are deemed more anxious than the one that venture
on the arms. The number of crossings into the arms and
the arm/bridge entries ratio are the only indices, which
are considered specific to anxiety. These proved consis-
tently reliable and concordant in all our studies.
The current tests of unconditioned tests of anxiety exert
an undue influence on the development of novel
approaches despite the accumulated evidence against their
validity, which is demonstrated through their inconsistent
and conflicting results. In this report, we argued that these
are based on flawed methodologies; they do not provide
unequivocal evidence of the presence of motivation con-
flict. They were adopted, and promoted based on reports
of their sensitivity to diazepam and chlordiazepoxide. This
sensitivity has been challenged when these tests proved
insensitive to benzodiazepine drugs in a second test expo-
sure, and demonstrated insensitivity to nonbenzodiazepine
drugs. Numerous reviews have been published each year to
highlight their achievements with some notes about their
shortcomings, and a list of improvement proposals to con-
solidate their status in animal anxiety research. One of
these proposals is to introduce ethological parameters,
which would complement the TUA spatiotemporal param-
eters, as the latter were unable to capture the construct
they were meant to measure (Griebel et al. 1997; Rodgers
and Dalvi 1997). The second proposal is the use of a bat-
tery of behavioral tests, in which results would hopefully
converge and determine the construct specificity (van Gaa-
len and Steckler 2000; V~oikar et al. 2004). A third proposal
is standardization, which would establish consistency and
improve interlaboratory comparisons (Crabbe et al. 1999;
Wahlsten 2001; Wu¨rbel 2002). The more recent proposal
is endophenotyping, which would use multidisciplinary
methodologies to characterize the traits of individuals with
anxiety and its disorders (Bakshi and Kalin 2002; Jacobson
and Cryan 2010). Simplicity in science research investiga-
tion is lost to very complex and expensive strategies, which
are no more than impressive correlations between data-
bases. All the above propositions look like desperate
attempts to salvage fundamentally flawed behavioral tests
that would continue to serve leading theories at the
expense of novel and daring approaches.
The decline in funding for basic research, particularly
in preclinical studies of anxiety, and the withdrawal of
industry from investing in such research is an issue of
concern for the future of animal research. “Is it poor
research the cause of the declining productivity of the
pharmaceutical industry” (Sams–Dodd 2013) or a “fund-
ing crisis in psychopharmacology” (Hendrie 2010)? The
complexity of the brain and the complexity of human
and animal behavior cannot be used to justify a long last-
ing failure. Researchers in other fields of science face sim-
2016 | Vol. 4 | Iss. 2 | e00223
Page 26
ª 2016 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
Preclinical Anxiety Research Methodology A. Ennaceur & P. L. Chazot
ilar complexities, and the secret of their success is that
exploration is not constrained by a-priori hypothesis and
established theories, and that popularity is the least of
their concern in the choice of a methodology. The intro-
duction of compulsory hypotheses and theories in
research grant applications prevent innovations; worse of
all, a vast majority of scientists are constrained to remain
aligned with the established views. The consequence of
this policy was evident when animal behavior research
proved unable to provide any satisfactory answer to the
emerging demand of molecular biology and genetic
manipulations. The limitations and the flaws of the classic
tests of anxiety were apparent from the start, but instead
of encouraging alternative and innovative approaches, the
established theories and hypothesis were left in control
and to self-perpetuate.
In this report, we exposed some major flaws that under-
mine the validity of the current TUA, and we described a
novel open space anxiety test, a 3D maze, which provides
more reliable measures of anxiety. It is not expected that
the findings from the 3D maze would replicate the find-
ings obtained in the TUA. The advantage of this novel
open space anxiety test over the current one is that (1)
Fear-induced avoidance is not confused with fear-induced
anxiety response; it is possible to demonstrate the differ-
ence between these two by introducing a refuge on the
central platform; (2) Anxiety response is determined by
the number of crossings into the arms and not by the time
spent in the arms. Two measurements are set to indicate
low or high anxiety mouse or rat strains: number of arm
entries and arm/bridge entries ratio; (3) A criterion of a
minimum of 8 arm visits and arm/bridge ratio close to 1
are required to determine an anxiolytic effect of a drug
treatment or an experimental intervention. An anxiogenic
effect is indicated by a number of arm visits lower than 8
and arm/bridge entries ratio lower than 50%; (4) mice
and rats can be tested in a number of sessions which pro-
vides the chance to examine slow acting drugs and habitu-
ation processes; (5) The bridges have been useful in
providing measure of locomotor activity, and they proved
to be a barrier that psychomotor stimulation cannot over-
come without a reduction in anxiety.
The results presented in this review originate from a
single laboratory, and are based on limited number of
animals and replications. They remain to be challenged in
independent laboratories, and it remains to be seen
whether the 3D maze can be used to predict the anxi-
olytic effects of novel drug compounds.
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